Skip to main content
. 2010 Jul 26;120(8):2655–2658. doi: 10.1172/JCI44026

Figure 2. Predicting responses using genetically engineered isogenic human cell lines.

Figure 2

Human mammary epithelial cells (WT) are subjected to gene targeting to create isogenic derivatives that contain a single PIK3CA oncogenic mutation (Mutant knock-in) or the same PIK3CA mutation along with a KRAS oncogenic mutation (Mutant double knock-in). Cells are then subjected to drugs in parallel, and resistance versus sensitivity can be assessed. Because the cell lines are isogenic, this allows for a clean interpretation of whether drug sensitivity is mediated by the presence or absence of a given mutation or set of mutations.